Compare · BYRN vs TMO
BYRN vs TMO
Side-by-side comparison of Byrna Technologies Inc. (BYRN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BYRN operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $222.03B, about 2868.8x BYRN ($77.4M).
- TMO has been more active in the news (16 items in the past 4 weeks vs 6 for BYRN).
- TMO has more recent analyst coverage (25 ratings vs 11 for BYRN).
- Company
- Byrna Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $3.39-5.70%
- $600.37-2.82%
- Market cap
- $77.4M
- $222.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 16
- Recent ratings
- 11
- 25
Byrna Technologies Inc.
Byrna Technologies Inc., a less-lethal defense technology company, develops and manufactures less-lethal munitions. The company offers a Byrna line of handheld personal security devices, including the Byrna HD, a .68 caliber handheld personal security device that is designed to be used by civilians and private security professionals, as well as Byrna HD magazines, launchers, and projectiles. It operates in the United States, Canada, and South Africa. The company was formerly known as Security Devices International, Inc. and changed its name to Byrna Technologies Inc. in March 2020. Byrna Technologies Inc. was incorporated in 2005 and is headquartered in Andover, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BYRN
- Byrna Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Byrna Appoints Retired U.S. Army Brigadier General Rose Lopez Keravuori to Board of Directors
- Amendment: SEC Form SCHEDULE 13D/A filed by Byrna Technologies Inc.
- Byrna Technologies Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Byrna Technologies Appoints Marketing Transformation Leader Nate Secor as Senior Vice President of Brand and Marketing
- Director Elmore Leonard J bought $46,400 worth of shares (10,000 units at $4.64), increasing direct ownership by 20% to 60,811 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Byrna Technologies Inc.
- Director Elmore Leonard J converted options into 4,865 shares, increasing direct ownership by 11% to 50,811 units (SEC Form 4)
- Director Hughes Herbert converted options into 4,865 shares, increasing direct ownership by 3% to 178,342 units (SEC Form 4)
- Chairman of the Board Kennedy Tj converted options into 4,379 shares, increasing direct ownership by 15% to 33,379 units (SEC Form 4)
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)